• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample.

作者信息

Kamili Abdulaziz, Ahmadi Paymon, Leypoldt Lisa, Marquard Franziska, Schaefers Christoph, Kosch Ricardo, Peters Frederik, Kusche Henrik, Zamrik Tanja, Hanoun Christine, Seib Maximilian, Shumilov Evgenii, Leitner Theo, Khandanpour Cyrus, Bokemeyer Carsten, Weisel Katja, Ghandili Susanne

机构信息

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf.

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf; Department of Medical Psychology, University Medical Center Hamburg-Eppendorf.

出版信息

Haematologica. 2024 Nov 1;109(11):3795-3799. doi: 10.3324/haematol.2024.285630.

DOI:10.3324/haematol.2024.285630
PMID:39021220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11532713/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af7/11532713/c8940496e805/1093795.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af7/11532713/c8940496e805/1093795.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af7/11532713/c8940496e805/1093795.fig1.jpg

相似文献

1
Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample.年轻患者的多发性骨髓瘤：基于德国全国登记数据和嵌套多中心样本对预后、临床特征及治疗结果的见解
Haematologica. 2024 Nov 1;109(11):3795-3799. doi: 10.3324/haematol.2024.285630.
2
Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.多发性骨髓瘤患者的临床特征与生存结局：来自韩国骨髓瘤登记处的基于网络数据的分析
Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29.
3
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.利用国家临床注册中心开发和验证多发性骨髓瘤疾病结局和治疗途径的离散事件仿真模型。
PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812. eCollection 2024.
4
Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.随机生存森林预测包括 FDG-PET 放射组学在内的新诊断多发性骨髓瘤移植候选者的结局：两项独立前瞻性欧洲试验的联合分析。
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1005-1015. doi: 10.1007/s00259-020-05049-6. Epub 2020 Oct 2.
5
Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.在常规治疗中，多发性骨髓瘤非移植患者的存活率与临床试验不同——来自前瞻性德国肿瘤登记处淋巴肿瘤的数据。
Ann Hematol. 2018 Dec;97(12):2437-2445. doi: 10.1007/s00277-018-3449-8. Epub 2018 Aug 1.
6
Multiple myeloma with central nervous system relapse.多发性骨髓瘤伴中枢神经系统复发。
Haematologica. 2020 Jul;105(7):1780-1790. doi: 10.3324/haematol.2020.248518. Epub 2020 May 15.
7
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.染色体 13 缺失和常规细胞遗传学上的亚二倍体是韩国多发性骨髓瘤患者强有力的预后因素：基于网络的多中心登记研究。
Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27.
8
Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study.新型药物时代诱导治疗的临床结果以及高危细胞遗传学异常（HRA）数量对初诊多发性骨髓瘤（NDMM）患者预后的影响：一项多中心研究的结果。
Cancer Med. 2024 Oct;13(20):e70270. doi: 10.1002/cam4.70270.
9
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.成功治疗肾功能受损的多发性骨髓瘤患者：4 家德国中心的结果。
Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):191-6. doi: 10.1016/j.clml.2012.01.001. Epub 2012 Feb 16.
10
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.合并症对多发性骨髓瘤死亡率的影响：一项基于丹麦全国人口的研究。
Cancer Med. 2017 Jul;6(7):1807-1816. doi: 10.1002/cam4.1128. Epub 2017 Jun 22.

引用本文的文献

1
A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.循环肿瘤浆细胞的病理生物学综述：浆细胞肿瘤预后不良的必要条件。
Oncol Res. 2025 Apr 18;33(5):1055-1068. doi: 10.32604/or.2024.055154. eCollection 2025.

本文引用的文献

1
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.40岁之前确诊的年轻多发性骨髓瘤患者的流行病学概况：法国的经验。
Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285.
2
Extramedullary multiple myeloma.髓外多发性骨髓瘤。
Leukemia. 2020 Jan;34(1):1-20. doi: 10.1038/s41375-019-0660-0. Epub 2019 Nov 27.
3
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT.
新诊断多发性骨髓瘤患者自体干细胞移植后髓外疾病的影响：来自 EBMT 慢性恶性肿瘤工作组的研究。
Haematologica. 2018 May;103(5):890-897. doi: 10.3324/haematol.2017.178434. Epub 2018 Feb 1.
4
AYA-Myeloma: Real-World, Single-Center Experience Over Last 5 Years.青少年及年轻成人多发性骨髓瘤：过去5年的真实世界单中心经验
J Adolesc Young Adult Oncol. 2018 Feb;7(1):120-124. doi: 10.1089/jayao.2017.0034. Epub 2017 Aug 22.
5
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.韩国极年轻多发性骨髓瘤患者的临床病理特征：治疗意义
Korean J Intern Med. 2017 Jul;32(4):722-730. doi: 10.3904/kjim.2016.256. Epub 2017 Jun 26.
6
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.21至40岁与41至60岁多发性骨髓瘤患者的特征及预后：一项多机构病例对照研究
Br J Haematol. 2016 Dec;175(5):884-891. doi: 10.1111/bjh.14328. Epub 2016 Sep 29.
7
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.高危细胞遗传学特征的多发性骨髓瘤的治疗：国际骨髓瘤工作组共识
Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.
8
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
9
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.骨髓瘤 IFM99 试验的长期分析：细胞遗传学异常 [t(4;14)、del(17p)、1q 增益] 在定义长期生存方面发挥着重要作用。
J Clin Oncol. 2012 Jun 1;30(16):1949-52. doi: 10.1200/JCO.2011.36.5726. Epub 2012 Apr 30.
10
Genomics in multiple myeloma.多发性骨髓瘤的基因组学。
Clin Cancer Res. 2011 Mar 15;17(6):1234-42. doi: 10.1158/1078-0432.CCR-10-1843.